GSK vet Jason Gardner takes the helm of Magenta, emerging from stealth with a $48.5M round
Jason Gardner, Magenta CEO. Jen Randall Photography.
Jason Gardner returned to his old stomping grounds in Cambridge, MA back in the fall of 2014 with a mission to hunt up new collaborations for the pharma giant GlaxoSmithKline. He’s staying on as CEO of an upstart biotech which is now coming out of stealth mode with a new platform tech under construction for stem cell transplants. And he’s building it with some of the top scientific hands in the field.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.